Search results
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 months agoMyriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call Transcript February 27, 2024 Myriad...
Myriad Genetics Inc (MYGN) Reports 23% YoY Revenue Growth in Q3 2023
GuruFocus.com via Yahoo Finance· 6 months agoMyriad Genetics Inc (NASDAQ:MYGN) reported a 23% YoY increase in Q3 2023 revenue, reaching $191.9...
Myriad Genetics Inc (MYGN) Reports 11% Revenue Growth in Q4 and Full-Year 2023
GuruFocus.com via Yahoo Finance· 2 months agoRevenue Growth: Myriad Genetics Inc (NASDAQ:MYGN) reported an 11% year-over-year increase in both Q4...
Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down
Zacks via Yahoo Finance· 2 months agoMyriad Genetics, Inc. MYGN reported an adjusted earnings per share (EPS) of 4 cents per share in the...
Insider Sell: CFO Richard Riggsbee Sells 30,000 Shares of Myriad Genetics Inc
GuruFocus.com via Yahoo Finance· 6 months agoOn November 1, 2023, Richard Riggsbee, the Chief Financial Officer (CFO) of Myriad Genetics Inc...
Here's Why Investors Should Hold Myriad Genetics (MYGN) Now
Zacks via Yahoo Finance· 2 years agoMyriad Genetics, Inc. MYGN has been gaining from continuous recovery in testing volumes. The robust...
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss
Zacks via Yahoo Finance· 9 months agoMyriad Genetics, Inc. MYGN reported an adjusted loss of 8 cents per share in the second quarter of...
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 221% Above Its Share Price
Simply Wall St. via Yahoo Finance· 4 months agoKey Insights Myriad Genetics' estimated fair value is US$57.52 based on 2 Stage Free Cash Flow to...
Myriad Genetics Q3 Earnings Fall Short Of Expectations, Lowers Annual Outlook
Benzinga via Yahoo Finance· 1 year agoMyriad Genetics Inc (NASDAQ: MYGN) has acquired Gateway Genomics LLC, a personal genomics company...
Myriad Genetics (MYGN) Teams Up to Assess Breast Cancer Risk
Zacks via Yahoo Finance· 8 months agoMyriad Genetics, Inc. MYGN recently announced the launch of a new breast cancer risk assessment...